Aim: The Norwegian government states that actions are needed to stimulate working capacity in disability pension (DP) recipients with such a potential. Identification of factors that may impair rehabilitation efforts, such as information on the start of benzodiazepines in DP recipients, may be useful in this context.Thus, the aim of the study was to describe the association between receipt of DP and later prescriptions of benzodiazepines among non-users at baseline. Methods: We followed a cohort reporting non-use of benzodiazepines, 6645 men and 6455 women aged 40-42 years who underwent health surveys in 1985-89 in two Norwegian counties, with respect to subsequent use of benzodiazepines by linkage to the Norwegian Prescription Database for [2004][2005][2006]. At baseline, 83 men and 163 women reported receiving DP. Results: In both genders, the proportion started on at least one prescription of a benzodiazepine was approximately doubled among those reporting being on a DP 20 years in the past, 21% of all men and 29% of all women, respectively. Univariate odds ratios for a benzodiazepine prescription for men and women on a DP were 2.6 (95% confidence interval (CI) ¼ 1.5-4.4) and 2.1 (95% CI ¼ 1.5-2.9), respectively, as compared with those not receiving a DP. After adjustment for alcohol use, smoking habits, physical activity, socioeconomic and health variables, the odds ratios were lowered for both genders, being 2.1 (95% CI ¼ 1.2-3.7) (men) and 1.6 (95% CI ¼ 1.1-2.3) (women). Conclusions: For both men and women, the chance of being prescribed benzodiazepines was higher among those reporting being DP recipients 20 years in the past.
Background
Despite above average life expectancy, Norway has a higher share of people on disability benefits than most other Organization for Economic Cooperation and Development (OECD) countries [1] . As a result, 11% of the working population (18-67 years) received a disability benefit in Norway in 2006 [2] . In Norway, an insured (National Insurance Scheme) person between 18-67 years of age, whose working capacity is permanently reduced by 50% due to illness, injury or defect, is entitled to a disability benefit. Today, two different disability benefit schemes exist in Norway: time-limited disability benefit and disability pension (DP). Traditionally a DP was granted on a permanent basis. However, during the last decade, the Norwegian government has introduced several policy changes to arrest the upward trend; the time-limited disability benefit including follow-up by the Norwegian Labour and Welfare Service was introduced to prevent claims for permanent DPs. In addition, initiatives aimed at the re-integration into the labour market of those already on a DP have been launched. The Norwegian government states, however, that further actions are needed to stimulate working capacity in disability pensioners with such a potential.
Several cross-sectional studies have shown that non-participation in the labour market seems to be associated with more frequent use of anxiolytics, hypnotics and/or benzodiazepines [3] [4] [5] [6] [7] . This association is, however, difficult to interpret in cross-sectional studies. The higher use among those not employed may, on the one hand, be explained by drug use as a proxy of mental illness, the precipitating reason for disability in the first place. On the other hand, and irrespective of the precipitating cause of disability, it is reasonable to believe that being on a DP may be associated with a number of psychological problems caused by, for instance, social isolation. Thus, drug treatment with anxiolytics, hypnotics and benzodiazepines may be initiated to relieve these symptoms.
It is well accepted that, even at therapeutic doses, benzodiazepines are capable of causing physiological and pharmacological dependence leading to withdrawal syndromes after cessation of use [8] . In addition, benzodiazepines impair psychomotor skills and cognitive functions, interfering with people's daily functioning [9] . Thus, initiation of benzodiazepines among disability benefit recipients might lead to a further impairment of health and rehabilitation efforts, contributing to a consolidation of the disability situation. Interestingly, randomized controlled trials have shown that withdrawal from benzodiazepines gives significantly better psychomotor function as compared to the control group remaining on benzodiazepines [10, 11] .
The Norwegian government states that large efforts will be needed to bring those of the disability pensioners who are able to work into employment. Identification of factors that may impair rehabilitation efforts, such as information on the initiation of benzodiazepines in DP recipients, may be useful in this context.
Aims
To our knowledge, the epidemiology of incident drug-taking behaviours in general, and that of use of benzodiazepines in particular, among disability pensioners are scarcely described in the literature. A longitudinal design, with data from the Norwegian health surveys in 1985-89 linked to data from a prescription database in 2004-2006, was used to investigate the association between the receipt of DP among 40-42-year-old non-users of benzodiazepines and prescriptions of benzodiazepines 20 years later, a span covering a large part of the potential active workforce period.
Material and methods

Health surveys: information on independent variables
All men (15, 606) and women (14, 748) aged 40-42 years in the two Norwegian counties of Østfold and Aust-Agder were invited to participate in a population-based health survey organised by the National Health Screening Service, which has been described previously [12] [13] [14] . The health survey was directed towards cardiovascular disease. Two examinations targeting two different generations aged 40-42 years at the time of survey were carried out with 3-year intervals, both in Østfold (1985 and 1988) and in Aust-Agder (1986 and 1989). The total response rate was high; 72% for men and 81% for women.
The participants completed a self-administered questionnaire covering different sociodemographic, health and lifestyle variables, such as disability status, smoking, physical activity and others. A physical examination comprised measurements of weight, height and blood pressure. At the examination site, an additional questionnaire was handed out to be filled in at home and returned by mail. All participants who where medically examined received this questionnaire. The response rate was 82%. The questionnaire included separate questions covering alcohol use, and use of analgesics, anxiolytics or hypnotics. In addition, in the surveys in 1988 and 1989 (and therefore a subsample of our study population), the second questionnaire included a question regarding nervous or mental health problems as diagnosed by the doctor. Details from the questionnaire, from which the variables are defined, are given in Table I .
We excluded from our study persons who died or emigrated from Norway (451 men and 326 women) before January 2004 ( Figure 1 ). In a second step, we removed all those who received drugs whose cost was reimbursed due to cancer diseases defined as code x9.9 in the reimbursement scheme (93 men and 80 women).
Furthermore, to study incident use of benzodiazepines, we excluded current users at baseline.
The participants reported whether they used anxiolytics or hypnotics in the answer to one question that did not distinguish between these two drug classes (Table I) . Benzodiazepines represented 99% of all sales of anxiolytics/hypnotics in the 1980s in Norway, and therefore anxiolytic/hypnotic users will be referred to as benzodiazepine users [15] . In total, 6645 men and 6455 women were defined as nonusers of benzodiazepines at baseline in 1985-89 according to this definition, and these persons were followed up with respect to subsequent prescription of benzodiazepines in 2004-2006. In parallel, among the participants who had received a questionnaire including a question regarding mental health symptoms, 3660 men and 3261 women were followed up with respect to subsequent prescription of benzodiazepines in 2004-2006. In addition to disability status, several other factors associated with the use of benzodiazepines were Table I . Questions and variable definition for drug use and other factors with answer alternatives used in the health survey in Østfold (1985 and 1988) and Aust Agder (1986 and 1989).
Self-administered questionnaire Answering alternatives Variable definition
Anxiolytics/hypnotics a How often have you used anxiolytics or hypnotics during the last month? a Daily (1); every week, but not daily (2) ; less often than every week (3); not used during the last month (4)
Users ¼ 1-3; non-users ¼ 4
Analgesics
How often have you used analgesics during the last month?
Daily (1); every week, but not daily (2); less often than every week (3); not used during the last month (4)
Alcohol consumption habits How often have you drunk beer, wine or spirits during the last 14 days?
Teetotaller (1); not during the last 14 days, but are not a teetotaller (2); 1-4 times (3); 5-10 times (4);410 times (5) included in our analysis: age, gender, alcohol consumption and smoking habits, marital status, physical activity, use of analgesics, and somatic (cardiovascular morbidity) and nervous/mental health problems. See Table I for details of questions and variable definitions. Analgesic users were defined as persons who reported that they had used analgesics daily or every week during the last month (Table I) . Persons who used analgesics less often than every week were defined as non-users according to probable common monthly use of analgesics among women due to menstrual pain. Analgesic use was defined in the same way for men.
Norwegian Prescription Database (NorPD): information on dependent variables
Prescription data on benzodiazepines in 2004-2006 were drawn from the NorPD, which covers the entire nation (4.6 million inhabitants) [16] . From 1 January 2004, all the pharmacies in Norway became legally obliged to send in all electronic data on prescriptions. These returns are sent to the Norwegian Institute of Public Health. The NorPD contains information on all individuals who have received prescription drugs dispensed at pharmacies. All prescriptions, reimbursed or not, are stored in the database. The drugs are classified according to the Anatomical Therapeutic Chemical (ATC) classification system [17] . The data collected for our study were patients' unique identifying numbers (encrypted), gender, age, date of dispensing, and drug information (brand name, package size, number of packages, ATC code, defined daily dose (DDD), price). The code of reimbursement is also recorded, and this may function as a proxy for diagnosis. Code x9.9 is dedicated to cancer diseases. The benzodiazepines were defined by the ATC codes N05BA and N05CD in the ATC classification system. Use of benzodiazepines was defined as at least one prescription of a benzodiazepine during the study period from 1 January 2004 to 31 December 2006.
In addition, and among benzodiazepine users, the amount of benzodiazepines used during the same period in terms of total DDDs was analysed.
Data from the health surveys and the NorPD were linked on the basis of the unique 11-digit identification number, assigned to all individuals living in Norway.
Statistics
The chi-square test was used to assess equality of proportions across the groups of drug users. Fisher's exact test was used when the expected counts in cells were less than 5. The Mann-Whitney test was used for variables with a skewed distribution. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated separately for men and women by logistic regression. All analyses were performed using SPSS 16.0 for Windows. The level of significance was set to p < 0.05.
Ethical considerations
The study protocol was assessed by the Regional Committee for Medical Research Ethics and approved by the Norwegian Data Inspectorate. The study was conducted in full accordance with the World Medical Association Declaration of Helsinki.
Results
Characteristics of the study population, non-users of benzodiazepines at baseline, are shown in Table II . The proportion of 40-42-year-old individuals reporting being receivers of a DP was approximately doubled in women (N ¼ 163; 2.5%) as compared to men (N ¼ 83; 1.3%) (Table II) . There was a higher prevalence of teetotallers, current daily smokers (women only) and physically inactive persons among receivers of a DP. There was also a higher prevalence of unmarried status, cardiovascular history and use of analgesic drugs among those reporting being on a DP.
In both genders, the proportion who received at least one prescription of a benzodiazepine 20 years later was approximately doubled among those reporting being on a DP when aged 40-42 years in 1985-89, 21% of all men and 29% of all women, respectively (Table II) . Furthermore, median DDDs of benzodiazepines retrieved among users during the study period were increased, but not significantly, among receivers of a DP in both genders, 50 vs. 30 DDDs, respectively (Table II) .
Univariate ORs for incident use of benzodiazepines among disability pensioners were 2.6 (95% CI ¼ 1.5-4.4) in men and 2.1 (95% CI ¼ 1.5-2.9) in women, respectively, as compared with those reporting to be non-receivers of a DP 20 years in the past (Table III) . After adjustment for lifestyle, health and socioeconomic variables, the ORs were lowered for both genders, being 2.1 (95% C ¼ 1.2-3.7) (men) and 1.6 (95% CI ¼ 1.1-2.3) (women).
Adjustment for nervous or mental health problems as diagnosed by the doctor was possible only in a subsample of the study population who had answered this question.
In gender-specific analyses, adjustment for mental health problems at baseline gave a higher OR for benzodiazepine use 20 years later in male disability pensioners (OR ¼ 2.6; 95% CI ¼ 1.3-5.5). The same trend was observed among women; however, the OR for later benzodiazepine use became non-significant (OR ¼ 1.4; 95% CI ¼ 0.8-2.2). Overall, adding adjustment for mental health problems and gender into the multivariate analysis revealed an OR for benzodiazepine use among receivers of a DP of 1.6 (95% CI ¼ 1.1-2.5).
Discussion
The proportion who had started benzodiazepines was doubled in those reporting being disability pensioners at the age of 40-42 years as compared to those reporting not being on a DP at baseline.
Our results may, to some extent, reflect what is generally well known; that benzodiazepine use increases with age. However, our design, comparing incident benzodiazepine use in DP recipients with the remaining population, highlight the fact that excessive incident benzodiazepine use may be attributed to the DP situation. This observation was supported by our multivariate analysis, where the receipt of a DP had an independent effect on incident use of benzodiazepines 20 years later, after controlling for alcohol, smoking habits and several other potential confounders. In Norway, and other OECD countries, mental health disorders and musculoskeletal problems are the main reasons for disability benefit claims [2] . Furthermore, cross-sectional studies have shown that mental health factors, anxiety disorders in particular, Adjusted for alcohol habits, smoking habits, physical activity, marital status, cardiovascular symptoms and use of analgesics. predict benzodiazepine use [7] . A higher incidence of benzodiazepine use among those reporting being on a DP may be explained by a higher prevalence of mental health symptoms in this group at baseline. However, adjusting for nervous/mental health problems, as diagnosed by the doctor, in a subgroup of our study population still revealed an independent effect of self-reported DP on use of benzodiazepines 20 years later, most pronounced in men. Obviously, limitations in using this variable to adjust for mental illness at baseline exist, and the results should be interpreted with caution. A discrepancy between the actual mental symptom load and the individual's response to this question may be caused by several factors, such as the respondent's recall, the subjective interpretation of the physician's message, and interpretation of the question in the questionnaire. It is a general observation that there exist two female benzodiazepine users for every male user of benzodiazepines, as reflected in prescription data among 60-69-year-olds as well as in the total Norwegian population [18] . Obviously, more women are started on benzodiazepines, as reflected in our results as well. The non-significant interaction supports the view that the risk ratio (or OR) between women and men in being prescribed a benzodiazepine is the same in people receiving and people not receiving a DP.
A limitation of our study is the description of use of benzodiazepines according to self-reported disability status 20 years in the past. The proportion on a DP increases with age; for example, in 2006 about 25% of all men and 37% of all women aged 60 years in Norway were receivers of a DP, as compared to 1-2% of the 40-42-year-old participants in our study [2] . Thus, an unknown number of the initially nondisabled 40-42-year-olds will have changed their disability status during this period. In this situation, the ORs as presented will be underestimated, and biased towards the null.
Another limitation is that no information is available on use prior to the period covered by the questionnaire or in the 20-year period between the two measurement points. It may very well be that some of the current users also used benzodiazepines regularly or in periods preceding the presentation of the questionnaire. Furthermore, in this study, benzodiazepine use is defined according to the retrieval of one prescription of a benzodiazepine during a 3-year period. In Norwegian recommendations, benzodiazepines are recommended for short-term use only, up to 2-4 weeks, in the treatment of severe anxiety and insomnia [19] . One prescription of a benzodiazepine is neither an outcome for long-term use nor an addictive use pattern, and should be interpreted with caution.
In the present study we chose to focus on later prescription of traditional benzodiazepines, with its well-known potential to cause addiction problems and other negative effects that interfere with people's daily functioning [8, 9] . Thus, we excluded prescriptions of benzodiazepine-like hypnotics from our analysis. In Norway, benzodiazepine-like hypnotics are now recommended as first-choice hypnotics for short-term use in severe insomnia. These substances, zopiclone in particular, are the most commonly used hypnotics in Norway. Hence, about 90% of all 60-69-year-olds who received at least one prescription of a hypnotic in Østfold and Aust-Agder in 2006 were users of benzodiazepine-like hypnotics [18] . Recent literature, however, adds to the growing evidence that these substances have a similar potential for negative effects as traditional benzodiazepines [20] [21] [22] . Nevertheless, we wanted to restrict our analysis to the prescription of the traditional benzodiazepines, which constitute a better documented marker of an addictive use pattern [14, 20, 23] .
This study is prospective, with a nationwide register as an endpoint, which implies minimal risk of selection or information bias. Another strength of our study is the narrow age range, since age as an important confounder is taken into account in the design. However, we cannot assess whether these findings are valid for other age groups. Furthermore, even though many potential confounders associated with prescription of benzodiazepines are registered, not all possible confounders could be taken into account. For example, we do not know the indication for later prescriptions of benzodiazepines. No evaluation of the non-attendees was performed in this study. However, receivers of DP were overrepresented among the non-attendees in a parallel Norwegian health survey [24] . Lower attendance of disability pensioners, presumably with the poorest health, will most likely have biased our OR estimates towards the null.
In conclusion, this prospective study provides evidence of an increased risk of the initiation of benzodiazepines among those reporting to be disability pensioners 20 years in the past. The limitations of our study design do not allow us to draw conclusions either on long-term use or on an addictive use pattern, for which there is a particular concern regarding the negative effects of benzodiazepines in interfering with people's daily functioning [9] . However, about 20% of all men and 30% of all women reporting being disability pensioners at the age of 40 years had started benzodiazepines 20 years later, a period covering most of their potential workforce period.
Being on a DP may be a positive alternative to joining the workforce. However, many disability pensioners perceive themselves to be passive and unwanted, and experience themselves as being excluded from the strong social and personal values associated with being a part of the workforce [25] . Re-integration into the labour market of disability pensioners with a working capacity has been an important part of the political agenda in Norway in the last decade. Our findings may highlight the need for further research in this area. More detailed information on the pattern of use of benzodiazepines among disability pensioners is needed to draw conclusions on ''problematic'' use, which has the potential to be yet another factor contributing to a consolidation of the disability situation.
